Company intelligence / Profile preview
Ensho Therapeutics
Morris Plains, New Jersey, United Statesenshorx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase 1 clinical program for NSHO-101 that evaluated 184 healthy subjects to assess safety, tolerability, food effects, PK and PD. NSHO-101 demonstrated target engagement, was generally safe and well-tolerated, with no appreciable increases in peripheral lymphocytes, suggesting gut-restricted activity. Recent data presented at ECCO 2025 showed that a once-daily formulation provided sustained, near-complete inhibition of MAdCAM-1 binding to α4β7 integrin with ≥95% receptor occupancy across the 24-hour dosing interval[2][6].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small moleculesoral therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
EA Pharma Co., Ltd.
Beyond the preview
Go deeper on Ensho Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ensho Therapeutics.